Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells
- 257 Downloads
Surgical resection of gastric cancer has made significant progress, but majority of patients with advanced gastric cancer face relapse and die within five years. In this study, the antitumor activity of ex vivo expanded T cells against the human gastric cancer was evaluated in vitro and in vivo. Human peripheral blood mononuclear cells were cultured with IL-2-containing medium in anti-CD3 antibody-coated flasks for 5 days, followed by incubation in IL-2-containing medium for 9 days. The resulting populations were mostly CD3+ T cells (97%) and comprised 1% CD3−CD56+, 36% CD3+CD56+, 11% CD4+, and 80% CD8+. This heterogeneous cell population was also called cytokine-induced killer (CIK) cells. CIK cells strongly produced IFN-γ, moderately TNF-α, but not IL-2 and IL-4. At an effector-target cell ratio of 30:1, CIK cells destroyed 58% of MKN74 human gastric cancer cells, as measured by the 51Cr-release assay. In addition, CIK cells at doses of 3 and 10 million cells per mouse inhibited 58% and 78% of MKN74 tumor growth in nude mouse xenograft assays, respectively. This study suggests that CIK cells may be used as an adoptive immunotherapy for gastric cancer patients.
Key wordsCytokine-induced killer cell Adoptive immunotherapy Human gastric cancer
Unable to display preview. Download preview PDF.
- De Vita, F., Giuliani, F., Orditura, M., Maiello, E., Galizia, G., Di Martino, N., Montemurro, F., Carteni, G., Manzione, L., Romito, S., Gebbia, V., Ciardiello, F., Catalano, G., and Colucci, G., Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann. Oncol., 18, 1354–1358 (2007).CrossRefPubMedGoogle Scholar
- Han, S. B., Park, S. H., Jeon, Y. J., Kim, Y. K., Kim, H. M., and Yang, K. H., Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J. Pharmacol. Exp. Ther., 299, 415–425 (2001).PubMedGoogle Scholar
- Han, S. B., Lee, C. W., Yoon, Y. D., Kang, J. S., Lee, K. H., Yoon, W. K., Kim, Y. K., Lee, K., Park, S. K., and Kim, H. M., Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. Biochem. Pharmacol., 70, 1518–1526 (2005).CrossRefPubMedGoogle Scholar
- Kim, H. M., Lim, J., Park, S. K., Kang, J. S., Lee, K., Lee, C. W., Lee, K. H., Yun, M. J., Yang, K. H., Han, G., Kwon, S. W., Kim, Y., and Han, S. B., Antitumor activity of cytokine-induced killer cells against human lung cancer. Int. Immunopharmacol., 7, 1802–1807 (2007b).CrossRefPubMedGoogle Scholar
- Kim, H. M., Lim, J., Yoon, Y. D., Ahn, J. M., Kang, J. S., Lee, K., Park, S. K., Jeong, Y. J., Kim, J. M., Han, G., Yang, K. H., Kim, Y. J., Kim, Y., and Han, S. B., Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int. Immunopharmacol., 7, 1793–1801 (2007c).CrossRefPubMedGoogle Scholar
- Kono, K., Rongcun, Y., Charo, J., Ichihara, F., Celis, E., Sette, A., Appella, E., Sekikawa, T., Matsumoto, Y., and Kiessling, R., Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer, 78, 202–208 (1998).CrossRefPubMedGoogle Scholar
- Kornacker, M., Moldenhauer, G., Herbst, M., Weilguni, E., Tita-Nwa, F., Harter, C., Hensel, M., and Ho, A. D., Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int. J. Cancer, 119, 1377–1382 (2006).CrossRefPubMedGoogle Scholar
- Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., Higashino, M., Yamamura, Y., Kurita, A., and Arai, K., Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med., 357, 1810–1820 (2007).CrossRefPubMedGoogle Scholar
- Shida, D., Kitayama, J., Mori, K., Watanabe, T., and Nagawa, H., Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res., 65, 9159–9163 (2005).CrossRefPubMedGoogle Scholar
- Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., and Kakizoe, T., Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 356, 802–807 (2000).CrossRefPubMedGoogle Scholar